{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43"},{"groupId":"OG001","value":"0.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Overall Response Rate (ORR) defined as patients by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 exhibited a complete or partial response (CR or PR). CR defined as disappearance of all target lesions. PR defined as \\>= 30% decrease in sum of the longest diameter of target lesions. .","groups":[{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV\n\nDocetaxel: Given IV\n\nEtoposide: Given IV\n\nPembrolizumab: Given IV","id":"OG000","title":"Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer"},{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2: Small Cell or Neuroendocrine Prostate Cancer"}],"paramType":"NUMBER","populationDescription":"one patient withdrew Cohort 2","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)","type":"PRIMARY","unitOfMeasure":"proportion of participents"}